281 related articles for article (PubMed ID: 24028669)
1. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
[TBL] [Abstract][Full Text] [Related]
2. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ.
Bradley C; Plowright R; Stewart J; Valentine J; Witthaus E
Health Qual Life Outcomes; 2007 Oct; 5():57. PubMed ID: 17927832
[TBL] [Abstract][Full Text] [Related]
3. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
4. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
5. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
6. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
7. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
8. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
9. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus.
Dailey G; Aurand L; Stewart J; Ameer B; Zhou R
J Diabetes; 2014 Mar; 6(2):176-83. PubMed ID: 23931125
[TBL] [Abstract][Full Text] [Related]
11. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
12. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
[TBL] [Abstract][Full Text] [Related]
14. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
Davies M; Evans R; Storms F; Gomis R; Khunti K
Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
Blonde L; Baron MA; Zhou R; Banerji MA
Postgrad Med; 2014 May; 126(3):172-89. PubMed ID: 24918802
[TBL] [Abstract][Full Text] [Related]
17. Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.
Freemantle N; Meneghini L; Christensen T; Wolden ML; Jendle J; Ratner R
Diabet Med; 2013 Feb; 30(2):226-32. PubMed ID: 23199058
[TBL] [Abstract][Full Text] [Related]
18. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study.
Polonsky WH; Thompson S; Wei W; Riddle MC; Chaudhari S; Jackson J; Bruno AS
Diabetes Obes Metab; 2014 Nov; 16(11):1121-7. PubMed ID: 24919603
[TBL] [Abstract][Full Text] [Related]
19. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
Berard L; Cameron B; Woo V; Stewart J
Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes.
Pandya N; DiGenio A; Gao L; Patel M
Drugs Aging; 2013 Jun; 30(6):429-38. PubMed ID: 23539233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]